Thank you, Mr. Ehsassi, for the question.
I do. I actually think it was a very strong approach. The government recognized early on that this was going to be a very fast moving space and that it did not have the expertise and the depth to quickly identify where the really promising technologies were going to be. It understood very well that it had to move quickly.
If I look at that task force both for the vaccines and also for the therapeutics.... If you recall back in the early days, some of the main thinking was that therapeutics were going to be the first things that would help us and the vaccines would come later—maybe three to five years later. Therapeutics were actually one of the first steps they moved into.
On both, they put together panels of experts that spread across a fairly wide and diverse areas of expertise. I think that was the prudent thing to do. You get not only expertise from a number of different key communities, but you also get the connections that a lot of those individuals bring to the table, particularly when you're dealing in a global context. It's the ability to reach out to other parts of the world and to other companies to connect and understand where things are moving and where the puck is going. I think that was absolutely critical.